Literature DB >> 22729370

Use of pharmacokinetic data below lower limit of quantitation values.

William J Jusko1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22729370      PMCID： PMC3422429          DOI： 10.1007/s11095-012-0805-6

Source DB:  PubMed          Journal:  Pharm Res        ISSN： 0724-8741            Impact factor:   4.200


× No keyword cloud information.
  14 in total

Review 1.  Modeling of dose-response-time data: four examples of estimating the turnover parameters and generating kinetic functions from response profiles.

Authors:  J Gabrielsson; W J Jusko; L Alari
Journal:  Biopharm Drug Dispos       Date:  2000-03       Impact factor: 1.627

2.  Ways to fit a PK model with some data below the quantification limit.

Authors:  S L Beal
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-10       Impact factor: 2.745

3.  Single-dose pharmacokinetics and pharmacodynamics of RWJ 67657, a specific p38 mitogen-activated protein kinase inhibitor: a first-in-human study.

Authors:  Dolly A Parasrampuria; Peter de Boer; Daksha Desai-Krieger; Andrew T Chow; C Richard Jones
Journal:  J Clin Pharmacol       Date:  2003-04       Impact factor: 3.126

4.  Impact of omission or replacement of data below the limit of quantification on parameter estimates in a two-compartment model.

Authors:  Vincent Duval; Mats O Karlsson
Journal:  Pharm Res       Date:  2002-12       Impact factor: 4.200

Review 5.  Diversity of mechanism-based pharmacodynamic models.

Authors:  Donald E Mager; Elzbieta Wyska; William J Jusko
Journal:  Drug Metab Dispos       Date:  2003-05       Impact factor: 3.922

6.  Assay detection limits: concept, definition, and estimation.

Authors:  A B Nix; D W Wilson
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

7.  Handling data below the limit of quantification in mixed effect models.

Authors:  Martin Bergstrand; Mats O Karlsson
Journal:  AAPS J       Date:  2009-05-19       Impact factor: 4.009

8.  Evaluation of pharmacokinetic studies: is it useful to take into account concentrations below the limit of quantification?

Authors:  H Humbert; M D Cabiac; J Barradas; C Gerbeau
Journal:  Pharm Res       Date:  1996-06       Impact factor: 4.200

9.  Fifteen years of operation of a high-performance liquid chromatographic assay for prednisolone, cortisol and prednisone in plasma.

Authors:  W J Jusko; N A Pyszczynski; M S Bushway; R D'Ambrosio; S M Mis
Journal:  J Chromatogr B Biomed Appl       Date:  1994-08-05

10.  Pharmacokinetics and pharmacodynamic modeling of direct suppression effects of methylprednisolone on serum cortisol and blood histamine in human subjects.

Authors:  A N Kong; E A Ludwig; R L Slaughter; P M DiStefano; J DeMasi; E Middleton; W J Jusko
Journal:  Clin Pharmacol Ther       Date:  1989-12       Impact factor: 6.875
View more
  9 in total

1.  Altered Hepatobiliary Disposition of Tolvaptan and Selected Tolvaptan Metabolites in a Rodent Model of Polycystic Kidney Disease.

Authors:  James J Beaudoin; Jacqueline Bezençon; Yanguang Cao; Katsuhiko Mizuno; Sharin E Roth; William J Brock; Kim L R Brouwer
Journal:  Drug Metab Dispos       Date:  2018-11-30       Impact factor: 3.922

2.  Describing Assay Precision-Reciprocal of Variance Is Correct, Not CV Percent: Its Use Should Significantly Improve Laboratory Performance.

Authors:  Roger W Jelliffe; Alan Schumitzky; David Bayard; Xiaowei Fu; Michael Neely
Journal:  Ther Drug Monit       Date:  2015-06       Impact factor: 3.681

3.  Population pharmacokinetic and pharmacodynamic modeling of capecitabine and its metabolites in breast cancer patients.

Authors:  Nastja Lunar; Marie-Christine Etienne-Grimaldi; Pauline Macaire; Fabienne Thomas; Florence Dalenc; Jean-Marc Ferrero; Xavier Pivot; Gérard Milano; Bernard Royer; Antonin Schmitt
Journal:  Cancer Chemother Pharmacol       Date:  2021-01-02       Impact factor: 3.333

4.  A quantitative LC-MS/MS method for determination of SP-141, a novel pyrido[b]indole anticancer agent, and its application to a mouse PK study.

Authors:  Subhasree Nag; Jiang-Jiang Qin; Shivaputra Patil; Hemantkumar Deokar; John K Buolamwini; Wei Wang; Ruiwen Zhang
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2014-08-28       Impact factor: 3.205

5.  Carfilzomib Delivery by Quinic Acid-Conjugated Nanoparticles: Discrepancy Between Tumoral Drug Accumulation and Anticancer Efficacy in a Murine 4T1 Orthotopic Breast Cancer Model.

Authors:  Yearin Jun; Jun Xu; Hyungjun Kim; Ji Eun Park; Yoo-Seong Jeong; Jee Sun Min; Naeun Yoon; Ji Yoon Choi; Jisu Yoo; Soo Kyung Bae; Suk-Jae Chung; Yoon Yeo; Wooin Lee
Journal:  J Pharm Sci       Date:  2020-01-13       Impact factor: 3.534

6.  Intranasal Coadministration of a Diazepam Prodrug with a Converting Enzyme Results in Rapid Absorption of Diazepam in Rats.

Authors:  Davin Rautiola; Patricia D Maglalang; Narsihmulu Cheryala; Kathryn M Nelson; Gunda I Georg; Jared M Fine; Aleta L Svitak; Katherine A Faltesek; Leah R Hanson; Usha Mishra; Lisa D Coles; James C Cloyd; Ronald A Siegel
Journal:  J Pharmacol Exp Ther       Date:  2019-03-05       Impact factor: 4.030

7.  Population pharmacokinetic and pharmacodynamic properties of artesunate in patients with artemisinin sensitive and resistant infections in Southern Myanmar.

Authors:  Jesmin Permala Lohy Das; Myat P Kyaw; Myat H Nyunt; Khin Chit; Kyin H Aye; Moe M Aye; Mats O Karlsson; Martin Bergstrand; Joel Tarning
Journal:  Malar J       Date:  2018-03-23       Impact factor: 2.979

8.  Population Pharmacokinetic and Pharmacodynamic Modeling of Artemisinin Resistance in Southeast Asia.

Authors:  Jesmin Lohy Das; Arjen M Dondorp; Francois Nosten; Aung Pyae Phyo; Warunee Hanpithakpong; Pascal Ringwald; Pharath Lim; Nicholas J White; Mats O Karlsson; Martin Bergstrand; Joel Tarning
Journal:  AAPS J       Date:  2017-09-11       Impact factor: 4.009

9.  Therapeutic Efficacy of Artemether-Lumefantrine for Uncomplicated Falciparum Malaria in Northern Zambia.

Authors:  Matthew M Ippolito; Julia C Pringle; Mwiche Siame; Ben Katowa; Ozkan Aydemir; Peter O Oluoch; Liusheng Huang; Francesca T Aweeka; Jeffrey A Bailey; Jonathan J Juliano; Steven R Meshnick; Theresa A Shapiro; William J Moss; Philip E Thuma
Journal:  Am J Trop Med Hyg       Date:  2020-10-15       Impact factor: 3.707
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.